Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter
February 05 2009 - 6:03PM
PR Newswire (US)
VALLEY COTTAGE, N.Y., Feb. 5 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) today
provided notification that on February 3, 2009 the Company received
a letter from a shareholder who owns more than 5% of the Company's
outstanding ordinary shares requesting the convening of an
extraordinary shareholders' meeting (EGM) of the Company as soon as
possible to address and approve the following matters: 1. that Boaz
Shweiger be and is hereby appointed as a Director of the Company
until the next annual general meeting of the Company; 2. that Mark
Allouche be and is hereby appointed as a Director of the Company
until the next annual general meeting of the Company; 3. that Amit
Yonay be and is hereby appointed as a Director of the Company until
the next annual general meeting of the Company; 4. that David
Grossman be and is hereby appointed as a Director of the Company
until the next annual general meeting of the Company; 5. that Yaron
Diament be and is hereby appointed as an External Director of the
Company until March 11, 2012; 6. that Dafna Cohen be and is hereby
appointed as an External Director of the Company until March 11,
2012; 7. that the share capital of the Company be consolidated and
re-divided so that each five (5) shares of NIS 0.02 nominal value
shall be consolidated into one (1) share of NIS 0.1 nominal value;
8. that the registered share capital of the Company be increased
from NIS 10,000,000 divided into 100,000,000 ordinary shares, NIS
0.1 nominal value, to NIS 70,000,000 divided into 700,000,000
ordinary shares, NIS 0.1 nominal value; 9. that the ADR ratio be
amended from one (1) ADR representing two (2) ordinary shares, NIS
0.1 nominal value, to one (1) ADR representing twenty (20) ordinary
shares, NIS 0.1 nominal value; 10. and that the remuneration terms
for Boaz Shweiger, Mark Allouche, Amit Yonay, David Grossman, Yaron
Diament and Dafna Cohen, as set forth in the Notice is hereby
approved. Upon the approval of the appointment of the aforesaid
Directors, all of the Company's current Directors shall immediately
tender their resignation. The EGMs will take place at the
Conference Room at the Company's Israeli offices at Building 3,
Kiryat Weizmann Science Park, Rehovot, Israel 76100, at 3:00 p.m.
and 5:30 p.m. Israel time on March 11, 2009. DATASOURCE: XTL
Biopharmaceuticals Ltd. CONTACT: Ron Bentsur, Chief Executive
Officer of XTL Biopharmaceuticals Ltd., +1-845-267-0707 ext. 224
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Sep 2024 to Oct 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Oct 2023 to Oct 2024